Disposition of voriconazole during continuous veno-venous haemodiafiltration (CVVHDF) in a single patient

Journal of Antimicrobial Chemotherapy

Volumn 54, Issue 1, 2004, Pages 269-270

  Robatel, C ^a   Rusca, M ^a   Padoin, C ^b   Marchetti, O ^a   Liaudet, L ^a   Buclin, Thierry ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b AVICENNE HOSPITAL   (France)

Author keywords

Antifungals; Dialysis; Pharmacokinetics; Renal failure

Indexed keywords

VORICONAZOLE;

ACUTE KIDNEY FAILURE; AGED; ARTICLE; ASPERGILLUS FUMIGATUS; CASE REPORT; CHRONIC KIDNEY FAILURE; CORRELATION COEFFICIENT; CRITICAL ILLNESS; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG HALF LIFE; FEMALE; HEMODIALYSIS; HEMOFILTRATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOSPITAL ADMISSION; HUMAN; LUNG ASPERGILLOSIS; MULTIPLE ORGAN FAILURE; PANCREATITIS; PLASMA CLEARANCE; PNEUMOCYSTIS PNEUMONIA; RESPIRATORY DISTRESS SYNDROME;

AGED; ANTIFUNGAL AGENTS; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FATAL OUTCOME; FEMALE; HALF-LIFE; HEMOFILTRATION; HUMANS; KIDNEY FAILURE, CHRONIC; PNEUMONIA, PNEUMOCYSTIS; PYRIMIDINES; RESPIRATORY DISTRESS SYNDROME, ADULT; TRIAZOLES;

EID: 3543134887     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh310     Document Type: Article

References (9)

1. Denning, D. W., Ribaud, P., Milpied, N. et al. (2002). Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clinical Infectious Diseases 34, 563-71.
2. Pearson, M., Rogers, P. D., Cleary, J. D. et al. (2003). Voriconazole: a new triazole antifungal agent. Annals of Pharmacotherapy 37, 420-32.
3. Purkins, L., Wood, N., Ghahramani, P. et al. (2002). Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrobial Agents and Chemotherapy 46, 2546-53.
4. Herbrecht, R., Denning, D. W., Patterson, T. F. et al. (2002). Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. New England Journal of Medicine 347, 408-15.
5. Forni, L. G. & Hilton, J. P. (1997). Continuous hemofiltration in the treatment of acute renal failure. New England Journal of Medicine 336, 1303-9.
6. Pennick, G. J., Clark, M., Sutton, D. A. et al. (2003). Development and validation of a high-performance liquid chromatography assay for voriconazole. Antimicrobial Agents and Chemotherapy 47, 2348-50.
7. Robatel, C., Decosterd, L. A., Biollaz, J. et al. (2003). Pharmacokinetics and dosage adaptation of meropenem during continuous venovenous hemodiafiltration in critically ill patients. Journal of Clinical Pharmacology 43, 1329-40.
8. Purkins, L., Wood, N., Greenhalgh, K. et al. (2003). The pharmacokinetics and safety of intravenous voriconazole - a novel wide-spectrum antifungal agent. Journal of Clinical Pharmacology 56, 2-9.
9. Pfizer Global Research & Development (2001). Briefing document for voriconazole, for the FDA Antiviral Drug Products Advisory Committee, pp. 1-56. [Online.] http://www.fda.gov/ohrms/dockets/ac/01/briefing/3792b2_01 _Pfizer.pdf (1 April 2004, date last accessed).